Quarterly Shareholder Report
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Syntara ended the quarter with a strong cash position, although it experienced a net cash outflow due to operating activities. The report emphasizes ongoing clinical trials and the company's strategic focus on advancing its drug development pipeline.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Syntara
- New positive interim data in Phase 2 study of SNT-5505
- SNT-5505 awarded US FDA Fast Track designation
- Quarterly Activities Report
- Acceleration of skin scarring program
- Placement
Later from Syntara
- Quarterly Appendix 4C Cash Flow Report
- Suspension from Quotation
- Reinstatement to Quotation
- Guidance from FDA on amsulostat clinical progression
- Preliminary Final Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara